Roivant an­nounces study win in eye dis­ease for Pfiz­er as­set, plans $1.5B share buy­back

Roivant has found a use for its ex­tra cash, and is re­veal­ing the lat­est da­ta from the big phar­ma re­la­tion­ship that helped gen­er­ate those funds.

On Tues­day, the drug de­vel­op­er made dual an­nounce­ments that it was start­ing a $1.5 bil­lion share re­pur­chase pro­gram that will buy out a long­time in­sid­er. And it an­nounced da­ta from the Phase 2 tri­al of bre­poc­i­tinib, a JAK1 and TYK2 in­hibitor that it ac­quired through the same part­ner­ship with Pfiz­er that led to a sep­a­rate $7.1 bil­lion deal with Roche last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER